Myasthenia Gravis

  • Richard S. A. Tindall
Part of the Foundations of Neurology book series (FONY, volume 1)


Myasthenia gravis literally means severe weakness; the name is derived from the observation that approximately one-third of all patients prior to 1960 died of direct complications of their illness. Initially a fatigue syndrome, the illness evolves to ptosis, diplopia, dysphagia, and dysarthria, shortness of breath, and ultimately respiratory insufficiency. Proximal weakness in the shoulder girdles, particularly of the deltoid, and in the hip girdle muscles, particularly of the iliopsoas, is ultimately prominent. Muscle atrophy is unusual except in long-standing severe cases with duration of more than two decades.


Acetylcholine Receptor Immunosuppressive Medication Hemorrhagic Cystitis Steroid Medication Drug Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grob D, Brunner NG, Namba T (1981). The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 377:652–669.PubMedCrossRefGoogle Scholar
  2. 2.
    NIH Consensus Development Conference (1986). The utility of plasmapheresis for neurological disorders. JAMA 256:1333–1337.CrossRefGoogle Scholar
  3. 3.
    Buckinghmam MB, Howard FM, Bernatz PE, et al. (1976). The value of thymectomy in myasthenia gravis. Ann Surg 184:453–458.CrossRefGoogle Scholar
  4. 4.
    Kennedy FS, Moersch FB (1937). Myasthenia gravis: Clinical review of 87 cases observed between 1915 and early part of 1932. Can Med Assoc J 17:216–223.Google Scholar
  5. 5.
    Grob D (1953). Course and management of myasthenia gravis. JAMA 153:529–532.Google Scholar
  6. 6.
    Simpson A (1958). An evaluation of thymectomy in myasthenia gravis. Brain 81:112–142.PubMedCrossRefGoogle Scholar
  7. 7.
    Oosterhuis HJGH (1964). Studies in myasthenia gravis. Part I. A clinical study of 180 patients. J Neurol Sci 1:512–546.CrossRefGoogle Scholar
  8. 8.
    Perlo VP, Arnason B, Poskanzer D, et al. (1971). The role of thymectomy in the treatment of myasthenia gravis. Ann NY Acad Sci 183:308–315.PubMedCrossRefGoogle Scholar
  9. 9.
    Mulder DG, Herrmann C, Buckberg GD (1974). Effect of thymectomy in patients with myasthenia gravis. Am J Surg 128:202–206.PubMedCrossRefGoogle Scholar
  10. 10.
    Papatestas AG, Genkins G, Kornfeld P, et al. (1975). Transcervical thymectomy in myasthenia gravis. Surg Gynecol Obstet 140:535–540.PubMedGoogle Scholar
  11. 11.
    Johns TR (1977). Treatment of myasthenia gravis: Long-term administration of corticosteroids with remarks on thymectomy. Adv Neuro 17:99–122.Google Scholar
  12. 12.
    Mertens HG, Hertel G, Reuther P, et al. (1987). Effect of immunosuppressive drugs (azathioprine). Ann NY Acad Sci 377:691–699.CrossRefGoogle Scholar
  13. 13.
    Schalke BDG, Kappos L, Rohrbach E, et al. (1988). Ciclosporin A vs. azathioprine in the treatment of myasthenia gravis: final results of a randomized, controlled double-blind clinical trial. Neurology 38 (Suppl 1):135.Google Scholar
  14. 14.
    Perez MC, Buot WL, Mercado-Danguilan C, et al. (1981). Stable remissions in myasthenia gravis. Neurology 31:32–37.PubMedGoogle Scholar
  15. 15.
    Tindall RSA, Rollins JR, Phillips JT, et al. (1981). Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719–724.CrossRefGoogle Scholar
  16. 16.
    Andres PL, Hedlund W, Finison L, et al. (1986). Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 36:937–941.PubMedGoogle Scholar
  17. 17.
    Vincent A (1988). Conclusions of Anti-AChR Workshop at Maastricht, June 1987. Monogr Allergy 25:150–153.Google Scholar
  18. 18.
    Besinger WA, Toyka KV, Homberg M, et al. (1983). Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316–1321.PubMedGoogle Scholar
  19. 19.
    Vincent A, Newson-Davis J, Newton P, et al. (1983). Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 33:1276–1282.PubMedGoogle Scholar
  20. 20.
    Tindall RSA, Phillips JT, Rollins JA, et al. (in press). A double-blinded, placebo-controlled, randomized clinical trial of cyclosporine in the treatment of steroid-dependent myasthenia gravis. Ann NeurolGoogle Scholar
  21. 21.
    Bourke GJ, Daly LE, McGilvay J (1985). Interpretation and Uses of Medical Statistics, third edition. Oxford: Blackwell, pp. 312–315.Google Scholar
  22. 22.
    O’Brien PC, Shampo MA (1981). Statistics of clinicians. 6. Comparing two samples (the two-sample t test). Mayo Clin Proc 56:393–394.PubMedGoogle Scholar
  23. 23.
    Snedecor GW, Cochran WG (1967). Statistical Methods, sixth edition. Iowa State University Press, Ames, 1A: pp. 130–134.Google Scholar
  24. 24.
    Cox DR (1984). Analysis of Survival Data. New York: Chapman & Hall.Google Scholar
  25. 25.
    O’Brien PC, Shampo MA (1988). Statistical considerations for performing multiple tests in a single experiment. 4. Performing multiple statistical tests on the same data. Mayo Clin Proc 63:1043–1045.PubMedGoogle Scholar
  26. 26.
    Tindall RSA, Phillips JT, Rollins JR, et al. (1988). Cyclosporin in the treatment of myasthenia gravis. Monogr Allergy 25:135–147.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Richard S. A. Tindall

There are no affiliations available

Personalised recommendations